SURMOUNT-OSA

Phase 3 clinical trial comparing tirzepatide with placebo in adults with moderate to severe obstructive sleep apnoea and obesity, showing at 52 weeks a greater reduction in the apnoea-hypopnoea index with the drug in both CPAP users and non-users.

Institutional endorsement by Clínica Evolution

This entry is for information. Your case requires an individual medical assessment.